A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
98actual
Sites
40
Countries
China, Germany, Israel +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-12 | actual | When the study began enrolling |
| Primary completion | 2024-10-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-02 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-21 | actual | When this record first appeared on the registry |
| Results posted | 2026-01-13 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Interventions
- Drug: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
- Drug: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured From date of first dose (Day 1) until date of progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-07-15 · 1.6 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-01-30 · 3.6 MB · SAP_001.pdf
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed